Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's

This page shows the latest Alzheimer's news and features for those working in and with pharma, biotech and healthcare.

Otsuka’s Alzheimers agitation drug hits the mark

Otsuka’s Alzheimer’s agitation drug hits the mark

pathology in Alzheimer’s – but nevertheless does address one of the most challenging symptoms in dementia care. ... bridge the treatment gap” in agitated Alzheimer’s patients, according to Avanir’s head of R&D  Sanjay Dubé.

Latest news

  • Undeterred by aducanumab failure, Eisai and Biogen plough on Undeterred by aducanumab failure, Eisai and Biogen plough on

    Investors sceptical, though mechanism different. Mere hours after reporting the failure of aducanumab in Alzheimer’s disease, Eisai has cued up a phase 3 trial of BAN2401, another amyloid-targeted drug. ... there is now a shift towards thinking about

  • Biogen and Eisai pull plug on Alzheimer’s drug Biogen and Eisai pull plug on Alzheimers drug

    The partners have a similar candidate, BAN2401, being studied in prodromal and mild Alzheimer’s patients, though its future must now also be under review. ... pipeline of potential therapies in Alzheimer’s disease and innovative medicines for

  • 23andMe to offer type 2 diabetes testing kit 23andMe to offer type 2 diabetes testing kit

    breast and ovarian cancer and late-onset Alzheimer’s. ... its efforts on medical devices that may pose inherent risks to a user’s safety.

  • Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022 Biogen, Eisai cue up BAN2401 readout in Alzheimers in 2022

    Also considering a trial in preclinical Alzheimer’s subjects. Biogen and Eisai spent the latter half of 2018 defending phase 2b results with their Alzheimer’s disease candidate BAN2401 against sceptics, ... BACE inhibitors are designed to an enzyme

  • GW Pharma's cannabis-based medicine to be tested in dementia GW Pharma's cannabis-based medicine to be tested in dementia

    Trial will be funded by Alzheimer’s Research UK. Alzheimer’s Research UK is to sponsor a clinical trial of GW Pharmaceuticals’ Sativex to treat agitation and aggression in people with ... Now the oral spray will now undergo testing to examine

More from news
Approximately 94 fully matching, plus 378 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 4 fully matching, plus 39 partially matching documents found.

Latest appointments

  • Cognite strengthens team with two new additions Cognite strengthens team with two new additions

    She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science

  • Metrion Biosciences establishes scientific advisory board Metrion Biosciences establishes scientific advisory board

    The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011. ... Alzheimer's disease.

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    In his new role, Prof De Strooper will work with the institute's founding partners - the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK - to develop new therapeutics

More from appointments
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest from PMHub

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases. ... Please contact us at info@random42.com to arrange a meeting. For more information on Random42’s capabilities please see

  • The dark side of direct-to-consumer genetic tests

    Who can blame them? If an email landed in your inbox that appeared to indicate you had an increased risk of cancer, Parkinson’s disease, Alzheimer’s disease, or any other

  • Attigo (part of the Mednet Group)

    Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK. ... Mednet Group's white paper with a focus on navigating the world of work is available online in aid of World Mental Health Day 2018.

  • Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

    the US suffer from Alzheimer’s disease, and  795, 000  Americans suffer from strokes annually. ... It’s a little bit like it was in the old days of buying IBM computers,” he says.

  • Synergy Vision

    Alzheimer's and Brain Awareness Month. ... June 2017 is Alzheimer’s and Brain Awareness Month, which aims to raise awareness about Alzheimer’s disease (AD) and other types of dementia.

More from PMHub
Approximately 3 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics